Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06228053 · ClinicalTrials.gov registry record · Phase 2

Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer

A Phase 2 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by Syntrix Biosystems.

Recruiting
Registry status
Phase 2
Development phase
53
Enrollment target
6
Study locations

NCT06228053 is a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer that is actively recruiting participants, run by Syntrix Biosystems. The registered enrollment target is 53 participants, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (73% lower). The trial reports 6 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06228053, a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer, is actively recruiting participants, sponsored by Syntrix Biosystems.

RECRUITING
Registry status
Phase 2
Development phase
53 participants
Enrollment target
6
Study locations

Study Summary

The goal of this clinical trial is to study the combination of SX-682 plus enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC) who have failed prior therapy with androgen receptor pathway inhibitors.

Conditions Studied

Metastatic Castration-Resistant Prostate Cancer

Interventions

  • DRUG Enzalutamide
  • DRUG SX-682

Study Locations (6)

California

  • University of California, Los Angeles - Los Angeles
  • University of California, San Francisco - San Francisco

Michigan

  • University of Michigan - Ann Arbor

Minnesota

  • University of Minnesota - Minneapolis

North Carolina

  • Duke University - Durham

Wisconsin

  • University of Wisconsin - Madison

Trial Details

FieldValue
Enrollment Target 53 participants
Start Date 2024-11-18
Est. Completion 2028-06-30
Phase Phase 2

Sponsor

Syntrix Biosystems

9 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06228053

The ClinicalTrials.gov registry entry for NCT06228053 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (73% lower). The listed sponsor is Syntrix Biosystems, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Enzalutamide is the first listed.

NCT06228053 reports 6 study locations spanning 5 distinct geographic areas - top geographies include California, Michigan, Minnesota.

Frequently Asked Questions

What is clinical trial NCT06228053 about?

NCT06228053 is a clinical study titled "Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer". The goal of this clinical trial is to study the combination of SX-682 plus enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC) who have failed prior therapy with androgen receptor pathway inhibitors.

What is the current status of trial NCT06228053?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2024-11-18. Estimated completion is 2028-06-30.

What conditions does trial NCT06228053 study?

This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.

What interventions are being tested in trial NCT06228053?

The interventions under investigation include: Enzalutamide (DRUG), SX-682 (DRUG).

Who is sponsoring clinical trial NCT06228053?

This trial is sponsored by Syntrix Biosystems, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06228053 being conducted?

This trial has 6 study locations across California, Michigan, Minnesota, North Carolina, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Castration-Resistant Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Castration-Resistant Prostate Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.